Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective
Open Access
- 3 February 2026
- journal article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10311-10326
Abstract
Renal cell carcinoma (RCC) is a prevalent malignancy of the urinary system. Despite significant advances achieved through targeted therapies and immunotherapies, therapeutic resistance remains a major obstacle to sustained clinical efficacy. This review comprehensively examines the molecular mechanisms driving resistance to both targeted therapy and immunotherapy in RCC from a multi-omics perspective. By integrating findings across diverse omics layers, we underscore the pivotal role of multi-level regulatory networks in mediating drug resistance and immune evasion. Our objective is to provide an in-depth understanding of these resistance mechanisms and to establish a theoretical framework for developing innovative therapeutic strategies aimed at overcoming resistance, thereby facilitating the advancement of precision oncology in RCC.Keywords
This publication has 179 references indexed in Scilit:
- Multiomics in Renal Cell Carcinoma: Current Landscape and Future Directions for Precision MedicineCurrent Urology Reports, 2025
- Renal Cell CarcinomaJAMA, 2024
- Renal cancer: signaling pathways and advances in targeted therapiesMedcomm, 2024
- Paraoxonase‐2 shRNA‐mediated gene silencing suppresses proliferation and migration, while promotes chemosensitivity in clear cell renal cell carcinoma cell linesJournal of Cellular Biochemistry, 2024
- Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell CarcinomaAdvanced Science, 2023
- RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activationCancer Immunology, Immunotherapy, 2021
- Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell CarcinomaDrugs, 2020
- PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaInternational Journal of Cancer, 2019
- Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancerTumor Biology, 2016
- Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy responseCancer Medicine, 2014